CNS SIDE EFFECTS OF ANTIHYPERTENSIVE THERAPIES

拟议的研究旨在评估以下物质的中枢副作用 通过多维、心理生物学手段进行降压治疗 评估方法。特别值得关注的是 睡眠结构、认知和知觉运动的治疗 表现、情绪状态和性功能。此外，潜在的 外周(循环和代谢)过程作为决定因素的作用 疲劳和其他中枢神经系统的影响将被调查。为了评估 长期服药和未接受治疗的患者的治疗效果，三 建议进行免费研究： 研究I将包括48名男性高血压患者的配对比较 接受长期心得安治疗的患者将与 对照组服用可乐定。将选出两个队列组 用于在每种药物条件下进行评估，以及相同数量的 有症状和无症状的患者将包括在内。该计划的目的是 研究旨在确定与患者相关的中枢神经系统效应的模式 昏昏欲睡和疲劳的主诉，并检验关于 调解这些影响。研究二是一项前瞻性的实验性研究。 80例初治男性高血压患者的临床评价 将被随机分配到药理学(心得安、可乐定、 安慰剂)，32名患者接受非药物治疗。完成 心理生物学评估将在每项评估前后进行。 治疗阶段。研究三由研究二的部分复制组成， 患有单纯性收缩期高血压的老年男性将接受 心得安、安慰剂或非药物治疗。后者的研究 将研究肾上腺素能抑制的生物行为后遗症 未经治疗的男性患者的非药物治疗。 综上所述，这些研究将提供对中枢神经系统的深入评估 与抗高血压治疗相关的副作用，将是 在高血压临床治疗中的价值。

The proposed research seeks to evaluate CNS side effects of antihypertensive therapies by means of a multidimensional, psychobiological assessment methodology. Of particular interest are the effects of treatment on sleep architecture, cognitive and perceptual-motor performance, mood state, and sexual function. Additionally, the potential role of peripheral (circulatory and metabolic) processes as determinants of fatigue and other CNS effects will be investigated. In order to assess the effects of treatment in chronically medicated and untreated patients, three complimentary studies are proposed: Study I will consist of a matched comparison in which 48 male hypertensive patients receiving long-term propranolol therapy will be compared to a matched group of patients on clonidine. Two cohort groups will be selected for evaluation within each drug condition, and an equal number of symptomatic and asymptomatic patients will be included. The purpose of the study is to identify patterns of CNS effects associated with patient complaints of drowsiness and fatigue, and to test hypotheses concerning the mediation of these effects. Study II is a prospective, experimental evaluation of 80 untreated male hypertensive patients, in which 48 patients will be randomly assigned to pharmacological (propranolol, clonidine, placebo), and 32 patients to non-pharmacological treatment. Complete psychobiological assessments will be conducted before and after each treatment phase. Study III consists of a partial replication of Study II, in which elderly males with isolated systolic hypertension will receive propranolol, placebo, or non-pharmacological therapy. The latter studies will investigate biobehavioral sequellae of adrenergic-inhibiting and non-pharmacological therapies in untreated male patients. Taken together, these studies will provide an in-depth evaluation of CNS side effects associated with antihypertensive treatment, and will be of value in the clinical management of hypertension.